WEBULL
News
QTRX
7.10
+1.43%
0.10
Weekly Report: what happened at QTRX last week (1208-1212)?
Weekly Report · 3d ago
Quanterix Corporation Files Initial Statement of Beneficial Ownership for Director Alan Bruce Sachs
Reuters · 12/08 14:33
Weekly Report: what happened at QTRX last week (1201-1205)?
Weekly Report · 12/08 09:47
Weekly Report: what happened at QTRX last week (1124-1128)?
Weekly Report · 12/01 09:44
Quanterix Corporation Files Initial Statement of Beneficial Ownership for Director Malcolm Garret Hampton
Reuters · 11/25 19:38
Weekly Report: what happened at QTRX last week (1117-1121)?
Weekly Report · 11/24 09:47
Quanterix Announces Leadership Changes to Drive Growth
TipRanks · 11/20 22:48
Quanterix names Bill Donnelly executive chair
TipRanks · 11/20 21:21
Quanterix Appoints New Board Members and Executive Chair
Reuters · 11/20 21:15
QUANTERIX CORP: APPOINTS WILLIAM DONNELLY AS EXECUTIVE CHAIR OF BOARD
Reuters · 11/20 21:15
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth
Barchart · 11/20 15:15
Quanterix Publishes A Landmark Study In The Journal Brain; Study Demonstrates Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring
Benzinga · 11/17 22:38
Quanterix Unveils Dual Biomarker Blood Test for Personalized Multiple Sclerosis Monitoring
Reuters · 11/17 22:30
Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring
Barchart · 11/17 16:30
Weekly Report: what happened at QTRX last week (1110-1114)?
Weekly Report · 11/17 09:47
Quanterix Q3 Earnings Call: Growth Amid Challenges
TipRanks · 11/12 00:11
Canaccord Genuity Sticks to Their Hold Rating for Quanterix (QTRX)
TipRanks · 11/11 12:26
Quanterix Reports Q3 2025 Financial Results
TipRanks · 11/11 04:03
Quanterix Corp Q3 Loss Increases, Misses Estimates
NASDAQ · 11/11 01:19
Quanterix: Hold Rating Amid Mixed Performance and Uncertain Revenue Outlook
TipRanks · 11/11 01:15
More
Webull provides a variety of real-time QTRX stock news. You can receive the latest news about Quanterix through multiple platforms. This information may help you make smarter investment decisions.
About QTRX
Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.